Follow
Giovanni Brandi
Title
Cited by
Cited by
Year
Prevalence of and risk factors for hepatic steatosis in Northern Italy
S Bellentani, G Saccoccio, F Masutti, LS Crocè, G Brandi, F Sasso, ...
Annals of internal medicine 132 (2), 112-117, 2000
18752000
The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses
V Gaboriau-Routhiau, S Rakotobe, E Lecuyer, I Mulder, A Lan, ...
Immunity 31 (4), 677-689, 2009
16162009
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo …
AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ...
The lancet oncology 20 (2), 282-296, 2019
14652019
Drinking habits as cofactors of risk for alcohol induced liver damage
S Bellentani, G Saccoccio, G Costa, C Tiribelli, F Manenti, M Sodde, ...
Gut 41 (6), 845-850, 1997
8901997
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double …
KM Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung ...
Lancet Oncology 16 (7), 859-70, 2015
8712015
Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
BS Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S ...
Hepatology, 2015
583*2015
Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention
D Colussi, G Brandi, F Bazzoli, L Ricciardiello
International journal of molecular sciences 14 (8), 16365-16385, 2013
5432013
Cholangiocarcinoma: Epidemiology and risk factors
SA Khan, S Tavolari, G Brandi
Liver International 39, 19-31, 2019
5382019
Interactions between commensal bacteria and gut sensorimotor function in health and disease
G Barbara, V Stanghellini, G Brandi, C Cremon, G Di Nardo, R De Giorgio, ...
Official journal of the American College of Gastroenterology| ACG 100 (11 …, 2005
4202005
Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?
M Renzulli, S Brocchi, A Cucchetti, F Mazzotti, C Mosconi, C Sportoletti, ...
Radiology 279 (2), 432-442, 2016
3092016
Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients
G Liguori, B Lamas, ML Richard, G Brandi, G Da Costa, TW Hoffmann, ...
Journal of Crohn's and Colitis 10 (3), 296-305, 2016
2912016
High prevalence of celiac disease in Italian general population
U Volta, S Bellentani, FB Bianchi, G Brandi, L De Franceschi, L Miglioli, ...
Digestive diseases and sciences 46, 1500-1505, 2001
2302001
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a …
RK Kelley, M Ueno, C Yoo, RS Finn, J Furuse, Z Ren, T Yau, HJ Klümpen, ...
The Lancet 401 (10391), 1853-1865, 2023
1842023
PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer
A Rizzo, AD Ricci, G Brandi
Cancers 13 (3), 558, 2021
1752021
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment?
M Di Marco, R Di Cicilia, M Macchini, E Nobili, S Vecchiarelli, G Brandi, ...
Oncology reports 23 (5), 1183-1192, 2010
1752010
Hypersensitivity reactions related to oxaliplatin (OHP)
G Brandi, MA Pantaleo, C Galli, A Falcone, A Antonuzzo, P Mordenti, ...
British journal of cancer 89 (3), 477-481, 2003
1732003
Mucosa-associated microbiota dysbiosis in colitis associated cancer
ML Richard, G Liguori, B Lamas, G Brandi, G Da Costa, TW Hoffmann, ...
Gut microbes 9 (2), 131-142, 2018
1722018
Intrahepatic cholangiocarcinoma: primary liver resection and aggressive multimodal treatment of recurrence significantly prolong survival
G Ercolani, G Vetrone, GL Grazi, O Aramaki, M Cescon, M Ravaioli, ...
Annals of surgery 252 (1), 107-114, 2010
1712010
Effect of vitamin A, C, and E supplementation on rectal cell proliferation in patients with colorectal adenomas
GM Paganelli, G Biasco, G Brandi, R Santucci, G Gizzi, V Villani, M Cianci, ...
JNCI: Journal of the National Cancer Institute 84 (1), 47-52, 1992
1481992
REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma …
AX Zhu, YK Kang, CJ Yen, RS Finn, PR Galle, JM Llovet, E Assenat, ...
Journal of Clinical Oncology 36 (15_suppl), 4003-4003, 2018
1452018
The system can't perform the operation now. Try again later.
Articles 1–20